Appropriate and effective rheumatoid arthritis control: Role of TNF antagonists

Drugs of Today

Volumn 39, Issue SUPPL. B, 2003, Pages 9-15

  Keystone, Edward C ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; LYMPHOTOXIN; METHOTREXATE; TUMOR NECROSIS FACTOR;

BLOOD TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DEMYELINATING DISEASE; DISEASE CONTROL; HUMAN; ONSET AGE; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; TUBERCULOSIS;

ARTHRITIS, RHEUMATOID; CLINICAL TRIALS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; HUMANS; QUALITY OF LIFE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0344876478     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Remicade package insert.
2. Enbrel package insert.
3. Humira package insert.
4. Maini, R., St. Clair, E.W., Breedveld, F. et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase II trial. Lancet 1999, 354: 1932-9.
5. Bathon, J.M., Martin, R.W., Fleischmann, R.M. et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000, 343: 1586-93.
6. Weinblatt, M.E., Keystone, E.C., Furst, D.E. et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48: 35-45.
7. Keystone, E., Sharp, J., Hua, Y. et al. Adalimumab (D2E7), a fully human anti-TNF-α monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy. Arthritis Rheum 2002, 46: S205.
8. Weinblatt, M.E., Kremer, J.M., Bankhurst, A.D. et al. Trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999, 340: 253-9.
9. Lipsky, P.E., van der Heijde, D.M., St. Clair, E.W. et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000, 343: 1594-602.
10. Moreland, L.W., Schiff, M.H., Baumgartner, S.W. et al. Etanercept therapy in rheumatoid arthritis. Ann Intern Med 1999, 130: 478-86.
11. van de Putte, L.B., Atkins, C., Malaise, M. et al. Adalimumab (D2E7) monotherapy in the treatment of patients with severely active rheumatoid arthritis. Arthritis Rheum 2002, 46: S205.
12. Kavanaugh, A., Lipsky, P., Furst, D. et al. Infliximab improves long-term quality of life and functional status in patients with rheumatoid arthritis. Arthritis Rheum 2000, 43(9 Suppl.): S147.
13. Lipsky, P.E., van der Heijde, D., St Clair, W. et al. 102-wk clinical & radiologic results from the ATTRACT: a 2 year, randomized, controlled, phase 3 trial of infliximab (Remicade) in patients with active RA despite MTX. Arthritis Rheum 2000, 43(9 Suppl.): S269.
14. Genovese, M.C., Bathon. J.M., Martin, R.W., Fleischmann, R.M., Tesser, J.R., Schiff, M.H. et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46: 1443-50.
15. Fleishman, R.M., Baumgartner, S.W., Moreland, L.W., Schiff, M.H., Markenson, J., Spencer-Green, G. Patient-reported outcomes (PRO) in rheumatoid arthritis (RA) patients treated with etanercept (ENEBREL®) for up to 5 years. Arthritis Rheum 2002, 46: S530.
16. Burmester, G.R., Van de Putte, L.B., Rau, R., Schattenkirchner, M., Hartz, D., Kupper, H. Sustained efficacy of adalimumab monotherapy for more than four years in DMARD-refractory RA. Ann Rheum Dis 2003, 62(Suppl. 1): 192.